CLOSEOUT LETTER
Loreal Usa
- Recipient:
- Loreal Usa
United States
- Issuing Office:
United States
5001 Campus Drive | |
AUG 1, 2017
Brigitte Liberman,
President Active Cosmetics Division
L'Oreal USA
575 Fifth Avenue
New York, NY 10017
Dear Ms. Liberman:
The Food and Drug Administration has completed an evaluation of your firm's corrective actions in response to our Warning Letter #440851 issued February 12, 2015. Based on our evaluation, it appears that you have addressed the violation(s) contained in this Warning Letter. Future FDA inspections and regulatory activities will further assess the adequacy and sustainability of these corrections.
This letter does not relieve you or your firm from the responsibility of taking all necessary steps to assure sustained compliance with the Federal Food, Drug, and Cosmetic Act and its implementing regulations or with other relevant legal authority. The Agency expects you and your firm to maintain compliance and will continue to monitor your state of compliance. This letter will not preclude any future regulatory action should violations be observed during a subsequent inspection or through other means.
Sincerely,
/S/
Latasha A. Robinson
Branch Chief
Dietary Supplements & Labeling Assessment Branch
Office of Compliance
Center for Food Safety
and Applied Nutrition